Default company panoramic image
Logo

COARE Biotechnology

A pre-clinical biotechnology company developing drugs for pancreatic, colon and solid tumor cancers based on targeting DCLK1.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Oklahoma City, OK, USA
  • Currency USD
  • Founded April 2010
  • Employees 8
  • Incorporation Type C-corp
  • Website coarebiotechnology.com

Company Summary

COARE Biotechnology is focused on treating pancreatic cancer by targeting cancer stem cells (CSCs), the cells responsible for early cancer growth and metastasis. COARE has used its initial funding to develop a therapeutic monoclonal antibody (drug) that blocks the function of a key cancer promoting protein. We are currently in the pre-clinical phase of drug development and intend to perform all of the studies required for IND.

Team

  • Default avatar
    Frank Griffith
    President

    He is cofounder and president of COARE. He brings proven leadership with 25 years experience in both sales and marketing in the pharmaceutical industry. He was a Brand Director for the Roche Hepatitis C Specialty Care Marketing Team.  Franks has an MBA from Fairleigh Dickinson University and MS from Seton Hall University.

  • Default avatar
    Courtney W Houchen MD
    Chief Medical Adviser and Founder

    Courtney W. Houchen, MD is founder and Chief Medical Adviser of COARE. He is a professor of medicine and holds the Frances and Malcolm Robinson Chair, and is the Chief of Digestive Diseases & Nutrition in the Department of Medicine at the University of Oklahoma Health Sciences Center (OUHSC). He received his M.D. degree at Temple University and was a fellow in gastroenterology at Washington University.

  • Default avatar
    Edwin Bannerman-Menson
    Chief Of Operations

    He is the Chief of Operations and Executive Business Manager of COARE. His overall responsibility includes the day-to-day management of the company. He is also responsible for the preparation, execution and management of COARE’s extramural funding activities.  Eddie has a BA from University of Missouri-St. Louis

  • Default avatar
    Ed Jarbath
    Chief Commercialization Officer

    20 years of biopharmaceutical experience, He served as the Managing Director of ScienceFirst, a leading strategic medical communications firm, where he advised and supported clients such as Merck, Pfizer, Novartis, AMGEN, and many other leading biopharmaceutical firms. He has worked in sales, sales and marketing management, finance and commercial development at increasing levels of responsibility, both domestically and internationally.

Advisors